JP2018537399A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537399A5
JP2018537399A5 JP2018510074A JP2018510074A JP2018537399A5 JP 2018537399 A5 JP2018537399 A5 JP 2018537399A5 JP 2018510074 A JP2018510074 A JP 2018510074A JP 2018510074 A JP2018510074 A JP 2018510074A JP 2018537399 A5 JP2018537399 A5 JP 2018537399A5
Authority
JP
Japan
Prior art keywords
seq
immunoglobulin
chain variable
variable region
region sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018510074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537399A (ja
JP6951825B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050213 external-priority patent/WO2017041001A2/en
Publication of JP2018537399A publication Critical patent/JP2018537399A/ja
Publication of JP2018537399A5 publication Critical patent/JP2018537399A5/ja
Application granted granted Critical
Publication of JP6951825B2 publication Critical patent/JP6951825B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018510074A 2015-09-04 2016-09-02 インスリン免疫グロブリン融合タンパク質 Active JP6951825B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214605P 2015-09-04 2015-09-04
US62/214,605 2015-09-04
PCT/US2016/050213 WO2017041001A2 (en) 2015-09-04 2016-09-02 Insulin immunoglobulin fusion proteins

Publications (3)

Publication Number Publication Date
JP2018537399A JP2018537399A (ja) 2018-12-20
JP2018537399A5 true JP2018537399A5 (enExample) 2019-10-03
JP6951825B2 JP6951825B2 (ja) 2021-10-20

Family

ID=58188627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510074A Active JP6951825B2 (ja) 2015-09-04 2016-09-02 インスリン免疫グロブリン融合タンパク質

Country Status (9)

Country Link
US (2) US10501546B2 (enExample)
EP (1) EP3344278A4 (enExample)
JP (1) JP6951825B2 (enExample)
KR (1) KR20180039726A (enExample)
CN (1) CN108348581B (enExample)
AU (1) AU2016315889A1 (enExample)
CA (1) CA2996716A1 (enExample)
HK (1) HK1258125A1 (enExample)
WO (1) WO2017041001A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1258125A1 (zh) 2015-09-04 2019-11-08 The California Institute For Biomedical Research 胰岛素免疫球蛋白融合蛋白
US12325732B2 (en) * 2018-09-12 2025-06-10 Amphastar Nanjing Pharmaceuticals Inc Pro-insulin aspart structure and method for preparing insulin aspart
WO2020072181A1 (en) * 2018-10-01 2020-04-09 University Of Houston System Engineered active single-polypeptide chain insulin analogs
WO2020083277A1 (zh) * 2018-10-22 2020-04-30 上海一宸医药科技有限公司 一种双特异性抗体
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
CN111041025B (zh) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
CN111744019B (zh) 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
GB2617717A (en) * 2020-11-27 2023-10-18 D&D Pharmatech Inc Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
WO2022114908A1 (ko) * 2020-11-27 2022-06-02 (주)디앤디파마텍 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체의 경구 제형
WO2025098472A1 (zh) * 2023-11-08 2025-05-15 北京拓界生物医药科技有限公司 融合蛋白及其医药用途
WO2025210538A1 (en) * 2024-04-02 2025-10-09 Biohaven Therapeutics Ltd. Bifunctional degraders
CN118834293B (zh) * 2024-08-06 2025-09-19 扬州大学 一种基于h5n8亚型禽流感病毒na的单克隆抗体及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
DK1983000T3 (en) 2003-11-21 2015-12-07 Ucb Biopharma Sprl A method for the treatment of multiple sclerosis by inhibiting IL-17 activity
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
EP1869084A2 (en) * 2005-03-04 2007-12-26 Biogen Idec MA Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US20110135725A1 (en) * 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
WO2008047914A1 (fr) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
FR2929509B1 (fr) 2008-04-02 2011-01-21 Lvmh Rech L'utilisation de glycosides d'alkyle ou de melanges de glycosides d'alkyle en tant qu'agents destines a inhiber la croissance microbienne, et compositions contenant lesdits glycosides d'alkyle.
NZ588857A (en) 2008-04-22 2012-07-27 Univ Case Western Reserve Isoform-specific insulin analogue for control blood sugar levels
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
JP2013516967A (ja) * 2010-01-14 2013-05-16 グラクソ グループ リミテッド 肝臓標的化ドメイン抗体
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
US20160009799A1 (en) * 2012-03-06 2016-01-14 Order-Made Medical Research Inc. Pharmaceutical composition for treating cancer
DK2822592T3 (en) * 2012-03-08 2018-10-15 Ludwig Institute For Cancer Res Limited TGF-1-SPECIFIC ANTIBODIES AND PROCEDURES AND APPLICATIONS THEREOF
MX2015001678A (es) * 2012-08-09 2015-08-14 Roche Glycart Ag Anticuerpos asgpr y sus usos.
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
LT3107563T (lt) 2014-02-21 2021-07-12 Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto Gliko-nukreipiantys terapiniai agenai
EP4640239A2 (en) 2014-03-19 2025-10-29 Genzyme Corporation Site-specific glycoengineering of targeting moieties
HK1258125A1 (zh) 2015-09-04 2019-11-08 The California Institute For Biomedical Research 胰岛素免疫球蛋白融合蛋白

Similar Documents

Publication Publication Date Title
JP2018537399A5 (enExample)
JP2018504907A5 (enExample)
JP2017176174A5 (enExample)
WO2016126858A3 (en) Antibodies directed against lymphocyte activation gene 3 (lag-3)
JP2017048194A5 (enExample)
JP2019524645A5 (enExample)
JP2016063812A5 (enExample)
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
WO2018151821A8 (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
JP2020513804A5 (enExample)
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
JP2017528117A5 (enExample)
JP2014237714A5 (enExample)
JP2018033454A5 (enExample)
WO2014186622A3 (en) Methods of treatment for guillain-barre syndrome
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
NZ626520A (en) Anti-lrp5 antibodies and methods of use
JP2016515524A5 (enExample)
JP2015523910A5 (enExample)
JP2021500874A5 (enExample)
WO2012047732A3 (en) Antibody compositions and methods of use
WO2015127140A3 (en) Marburg monoclonal antibodies